A number of generic drugmakers are aiming to resolve a criminal antitrust probe launched by the US Justice Department (DOJ), a report from Bloomberg stated.
One potential resolution would be a deferred prosecution agreement, in which the companies would admit to some of the agency’s allegations, pay fines, and cooperate with the inquiry but would not be indicted, people familiar with the matter told Bloomberg.
The talks aren’t certain to lead to agreements with any or all of the companies, the news service reported. Teva Pharmaceutical of Israel and Sun Pharmaceutical of India have been in talks with the justice agency, Bloomberg reported.
Teva told Bloomberg that it was cooperating with the DOJ and would consider resolving the matter if an accord “makes sense for the company,” its holders, and the patients who rely on the company’s products.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
